With olaparib now available to patients as tablets for the first-line maintenance therapy and treatment for recurrent disease in women with advanced ovarian cancer, there is a need to educate clinicians on the implications of switching patients from capsules to tables. The recent article ‘Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data’ published in Future Oncology addresses this issue by discussing real-world data from US patients who have switched from olaparib capsules to tablets and providing insights into the tolerability of switching between olaparib formulation.
This Publication Perspective video, by lead author Susana Banerjee from the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, provides an overview of this article, helping readers learn more about the publication and it’s relevance to them.
About the author:
Dr Susana Banerjee (MBBS MA PhD FRCP) is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at the Royal Marsden, London, UK. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Dr. Banerjee graduated with a 1st class from St. John’s College, University of Cambridge. She gained a PhD from the Institute of Cancer Research, University of London and completed specialist training at The Royal Marsden. Dr Banerjee has been involved in several national and international specialist groups including the National Cancer Research Institute (NCRI) Gynaecological Cancers Clinical Studies Group, European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, and ESGO (European Society of Gynaecological Oncology) Congress Faculty. Dr Susana Banerjee serves on the European Society of Medical Oncology (ESMO) Executive Board as Director of Membership. She was the Track Chair for Gynaecological Cancers at ESMO Congress 2018 and Scientific Co-Chair for ESMO Asia 2018.
Dr Banerjee is an author of over 100 peer-reviewed publications and is actively involved in clinical trials and translational research. Dr Banerjee is UK Chief Investigator and Principal Investigator at the Royal Marsden for multiple national and international clinical trials. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers.
Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data
Susana Banerjee, Richard Davidson, Kimmie McLaurin, William Sawyer & Gráinne H Long